Keyword: Ariad Pharmaceuticals
UCSF scientist Shaun Coughlin will lead CV research at NIBR, Novo's China GM was promoted to EVP, and Cavion poached Teva exec to head up R&D.
Perrigo CEO Hendrickson will retire after just over a year on the job, Johnson & Johnson has poached Merck exec Mammen to head pharma R&D, and more.
Following a major reorganization earlier this year that saw it sell off its marketed med and revert back to being a clinical-stage biotech, Merrimack is making major changes in its executive team, announcing today that former Ariad chief medical officer Sergio Santillana, M.D., will be its new medical lead.
Ariad Pharmaceuticals has finished sending its latest data for brigatinib to the FDA and is now looking to the U.S. regulator for a speedy review.